Novartis investing $23 billion to expand production and R&D in USA

Swiss pharma giant Novartis (NOVN: VX) has announced a planned $23 billion investment over five years in US-based infrastructure, ensuring all key Novartis medicines for US patients will be made in the USA.

The planned US investment comes as President Donald Trump has repeatedly threatened to subject pharmaceuticals to high tariff rates. Major pharmaceutical companies – including Eli Lilly (NYSE: LLY), Pfizer (NYSE: PFE) and Merck & Co (NYSE: MRK) - are also ramping up manufacturing investments in the USA to navigate the evolving trade tariffs and capitalize on domestic tax incentives.

This commitment enables Novartis to expand on its current manufacturing, research and technology presence across the country with 10 facilities, including seven brand new facilities, creating nearly 1,000 new jobs at Novartis and approximately 4,000 additional US jobs. The production capacity will cover both active pharmaceutical ingredients (API) and biologics drug substance, as well as secondary production and packaging.